-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: iHuPBMC-T Technology, a New Solution for Cell Therapy Research
Author:
InnoModels
Release time:
2024-02-28
In recent years, cell therapy technology has attracted much attention worldwide, and more and more research institutes and pharmaceutical companies have devoted themselves to research and development in this field. However, the key technical bottlenecks in cell therapy research have been restricting the rapid development of this field. In this regard, InnoModels Biotechnology has independently developed an innovative technology, iHuPBMC-T, which provides a brand new solution for cell therapy research.
iHuPBMC-T is a kind of mouse T cell with human T cell receptor (TCR) by fusing human peripheral blood mononuclear cell (PBMC) with mouse T cell using genetic engineering technology. This cell has both the human TCR, which recognizes and attacks specific human tumor cells, and the mouse immune system, which enables in vivo testing in mice.
The iHuPBMC-T technology introduced by InnoModels Biotechnology has the following advantages:
1. High recognition ability: iHuPBMC-T cells possess human TCR, which can highly recognize and attack specific human tumor cells.
2. High safety: iHuPBMC-T cells are derived from human peripheral blood single nucleus cells, which reduces the risk of immune rejection and tumor metastasis.
3. Wide range of application: iHuPBMC-T cells can be used in clinical trials for a variety of tumors, including solid tumors and hematological tumors, etc., which has a wider application potential.
4. Easy to operate: The preparation and application process of iHuPBMC-T cells is relatively simple, which helps the rapid advancement of research and clinical trials.
5. Avoidance of immune rejection: Due to the use of human PBMC, iHuPBMC-T cells can theoretically reduce immune rejection and improve the feasibility of treatment.
6. Tumor specificity: iHuPBMC-T cells can target specific tumor antigens, improving the precision of treatment.
7. Promoting immune memory: iHuPBMC-T cell treatment may activate immune memory, thus creating a long-term anti-tumor immune environment in the body.
8. Customizability: Depending on different tumor types and patient conditions, iHuPBMC-T cells can be customized and prepared to fit specific therapeutic needs.

With iHuPBMC-T technology, InnoModels Biotechnology brings innovative solutions to the field of cell therapy, which is expected to provide safer, more effective and more personalized treatment options for tumor patients.
InnoModels Biotechnology is committed to applying iHuPBMC-T technology in clinical practice, bringing new therapeutic hope to tumor patients around the world. The company has cooperated with many well-known pharmaceutical companies and research institutes at home and abroad to jointly promote the research and development of cell therapy technology.
In the future development, InnoModels Biotechnology will continue to increase its R&D efforts to optimize iHuPBMC-T technology and provide more innovative solutions for the cell therapy field. At the same time, the company will also join hands with its partners to jointly promote China's cell therapy business to a higher level and help the development of human health.
In conclusion, iHuPBMC-T technology independently developed by InnoModels Biotechnology provides a brand-new solution for cell therapy research, which is expected to bring a brand-new therapeutic hope to global tumor patients. In the wave of cell therapy field, InnoModels Biotechnology will continue to play a role in promoting the development of this field to new heights.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd